Bio Impact Capital LLC Cullinan Oncology, Inc. Transaction History
Bio Impact Capital LLC
- $641 Million
- Q3 2024
A detailed history of Bio Impact Capital LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Bio Impact Capital LLC holds 7,648,268 shares of CGEM stock, worth $96.2 Million. This represents 19.97% of its overall portfolio holdings.
Number of Shares
7,648,268
Previous 7,648,268
-0.0%
Holding current value
$96.2 Million
Previous $133 Million
4.01%
% of portfolio
19.97%
Previous 21.42%
Shares
2 transactions
Others Institutions Holding CGEM
# of Institutions
146Shares Held
67.6MCall Options Held
612KPut Options Held
118K-
Bvf Inc San Francisco, CA5.75MShares$72.3 Million3.06% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$44.7 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$43 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.28MShares$41.3 Million1.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA3MShares$37.7 Million0.0% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $574M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...